The outcome of any clinical study is uncertain but the choice of active comparator and sometimes even the placebo arm can magnify unpredictability. Emgality’s recent head-to-head failure in migraine is just the latest in a long list of casualties.

Recent mergers between PBMs and insurers should address one long-term strategic objective of pharma – the recognition by payors of the value of biopharmaceutical products in relation to other medical costs.

US Centers for Medicare and Medicaid Services announces first-year results from its medication therapy management model, intended to optimize prescription drug use among Medicare beneficiaries.

Divestiture prevents CVS from gaining even more dominance in the stand-alone Medicare Part D sector with its acquisition of Aetna, assuming the transaction is cleared by the government.